Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development
Skinvisible Pharmaceuticals (OTCQB:SKVI) announced the publication of an article in Drug Development & Delivery highlighting its innovative development of transdermal delivery of glucose-controlling agents using its proprietary Invisicare® technology. Key findings include:
1. A GLP-1 active formulation showed 99.6% transdermal delivery over six hours.
2. CB-1 antagonists demonstrated 62% penetration over six hours.
3. Formulations exhibited sustained drug delivery without initial spikes.
The company has filed two provisional patent applications for these formulations. Skinvisible's CEO, Terry Howlett, emphasized the potential of their topical formulations to avoid side effects associated with oral pills and injections while increasing patient compliance. The global obesity drug market is projected to reach $105-144 billion by 2030. Skinvisible is seeking strategic partnerships to bring the first transdermal obesity therapies to market.
Skinvisible Pharmaceuticals (OTCQB:SKVI) ha annunciato la pubblicazione di un articolo su Drug Development & Delivery che mette in evidenza lo sviluppo innovativo della somministrazione transdermica di agenti di controllo della glicemia utilizzando la propria tecnologia proprietaria Invisicare®. I risultati principali includono:
1. Una formulazione attiva di GLP-1 ha mostrato una somministrazione transdermica del 99,6% in sei ore.
2. Gli antagonisti del CB-1 hanno dimostrato una penetrazione del 62% in sei ore.
3. Le formulazioni hanno mostrato una somministrazione sostenuta del farmaco senza picchi iniziali.
La società ha presentato due domande di brevetto provvisorio per queste formulazioni. Il CEO di Skinvisible, Terry Howlett, ha sottolineato il potenziale delle loro formulazioni topiche per evitare effetti collaterali associati a pillole orali e iniezioni aumentando al contempo la compliance dei pazienti. Si prevede che il mercato globale dei farmaci per l'obesità raggiunga i 105-144 miliardi di dollari entro il 2030. Skinvisible sta cercando partnership strategiche per portare sul mercato le prime terapie per l'obesità transdermiche.
Skinvisible Pharmaceuticals (OTCQB:SKVI) anunció la publicación de un artículo en Drug Development & Delivery que destaca su desarrollo innovador de liberación transdérmica de agentes para el control de la glucosa utilizando su tecnología patentada Invisicare®. Los hallazgos clave incluyen:
1. Una formulación activa de GLP-1 mostró un 99.6% de liberación transdérmica durante seis horas.
2. Los antagonistas de CB-1 demostraron una penetración del 62% durante seis horas.
3. Las formulaciones presentaron una liberación sostenida del fármaco sin picos iniciales.
La empresa ha presentado dos solicitudes de patente provisional para estas formulaciones. El CEO de Skinvisible, Terry Howlett, enfatizó el potencial de sus formulaciones tópicas para evitar efectos secundarios asociados con pastillas orales e inyecciones mientras aumentan la adherencia de los pacientes. Se proyecta que el mercado global de medicamentos para la obesidad alcanzará entre 105 y 144 mil millones de dólares para el año 2030. Skinvisible está buscando alianzas estratégicas para llevar al mercado las primeras terapias transdérmicas para la obesidad.
스킨비저블 제약 (OTCQB:SKVI)는 그들의 독창적인 기술인 Invisicare®를 이용한 혈당 조절 물질의 경피 전달 혁신적인 개발을 강조하는 Drug Development & Delivery에 기사를 발표했다고 알렸습니다. 주요 발견 사항은 다음과 같습니다:
1. GLP-1 활성 성분이 6시간 동안 99.6%의 경피 전달을 보였습니다.
2. CB-1 길항제는 6시간 동안 62%의 침투를 나타냈습니다.
3. 제형은 초기 피크 없이 지속적인 약물 전달을 보여주었습니다.
회사는 이러한 제형에 대해 두 건의 임시 특허 출원을 했습니다. 스킨비저블의 CEO 테리 하우렛(Terry Howlett)은 그들의 국소 제형이 경구약과 주사와 관련된 부작용을 피할 수 있는 잠재력이 있으며 환자의 순응도를 증가시키는 데 기여한다고 강조했습니다. 전 세계 비만 약물 시장은 2030년까지 1,050억에서 1,440억 달러에 이를 것으로 예상됩니다. 스킨비저블은 최초의 경피 비만 치료제를 시장에 출시하기 위해 전략적 파트너십을 모색하고 있습니다.
Skinvisible Pharmaceuticals (OTCQB:SKVI) a annoncé la publication d'un article dans Drug Development & Delivery mettant en avant son développement innovant de libération transdermique d'agents de contrôle de la glycémie grâce à sa technologie propriétaire Invisicare®. Les principales conclusions incluent :
1. Une formulation active de GLP-1 a montré une libération transdermique de 99,6 % sur six heures.
2. Les antagonistes de CB-1 ont démontré une pénétration de 62 % sur six heures.
3. Les formulations ont présenté une délivrance durable du médicament sans pics initiaux.
L'entreprise a déposé deux demandes de brevet provisoire pour ces formulations. Le PDG de Skinvisible, Terry Howlett, a souligné le potentiel de leurs formulations topiques pour éviter les effets secondaires associés aux pilules orales et aux injections tout en augmentant la conformité des patients. Le marché mondial des médicaments contre l'obésité devrait atteindre entre 105 et 144 milliards de dollars d'ici 2030. Skinvisible recherche des partenariats stratégiques pour commercialiser les premières thérapies transdermiques contre l'obésité.
Skinvisible Pharmaceuticals (OTCQB:SKVI) hat die Veröffentlichung eines Artikels in Drug Development & Delivery angekündigt, der die innovative Entwicklung von transdermaler Abgabe von glucoseregulierenden Agentien unter Verwendung ihrer proprietären Technologie Invisicare® hervorhebt. Die wichtigsten Ergebnisse umfassen:
1. Eine aktive GLP-1-Formulierung zeigte eine transdermale Abgabe von 99,6% über sechs Stunden.
2. CB-1-Antagonisten zeigten eine Penetration von 62% über six Stunden.
3. Die Formulierungen wiesen eine anhaltende Arzneimittelabgabe ohne anfängliche Spitzen auf.
Das Unternehmen hat zwei vorläufige Patentanmeldungen für diese Formulierungen eingereicht. Der CEO von Skinvisible, Terry Howlett, betonte das Potenzial ihrer topischen Formulierungen, um Nebenwirkungen im Zusammenhang mit oralen Pillen und Injektionen zu vermeiden und gleichzeitig die Compliance der Patienten zu erhöhen. Der globale Markt für Adipositas-Medikamente wird bis 2030 voraussichtlich 105-144 Milliarden Dollar erreichen. Skinvisible sucht strategische Partnerschaften, um die ersten transdermalen Adipositas-Therapien auf den Markt zu bringen.
- Successful development of transdermal delivery for glucose-controlling agents using Invisicare® technology
- High transdermal penetration rates: 99.6% for GLP-1 active and 62% for CB-1 antagonists over 6 hours
- Filed two provisional patent applications for transdermal formulations
- Potential to avoid side effects associated with oral pills and injections
- Targeting a rapidly growing obesity drug market projected to reach $105-144 billion by 2030
- None.
Drug Development & Delivery Publishes Overview of Obesity Formulation Development Results Demonstrating Significant Transdermal Penetration Using Invisicare Technology
LAS VEGAS, NV / ACCESSWIRE / October 3, 2024 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical pharmaceutical research and development company, today announced the publication of an article highlighting the Company's innovative development of transdermal delivery of glucose-controlling agents using its proprietary delivery system Invisicare®. The article, titled "Advancements in Transdermal Delivery Systems: A Focus on Invisicare Technology for Obesity Treatment," was published in Drug Development & Delivery in its October issue.
"The data published in Drug Development & Delivery demonstrates that our Invisicare based transdermal formulation of a GLP-1 active, showed significant (
Key benefits of Invisicare transdermal obesity formulations:
Invisicare technology; a polymer delivery vehicle does not require a patch or needles for transdermal delivery;
The Company previously announced it has filed two provisional patent applications covering formulations that leverage Invisicare for the transdermal administration of glucose-controlling agents;
The results from Franz cell diffusion studies demonstrated compelling results:
GLP-1 drug (danuglipron) formulated with Invisicare showed a
99.6% penetration over 6 hours;CB-1 antagonists formulated with Invisicare, showed a
62% penetration over 6 hours;Formulations showed a sustained drug delivery over time, with no initial spike;
This data opens up exciting opportunities compelling the Company to expand its portfolio of obesity-targeting formulations with other active ingredients;
Other small molecules, both in the obesity space and other indications, have the potential to be delivered by Invisicare technology.
"Skinvisible's Invisicare technology offers a novel approach to obesity drug administration," said Terry Howlett, President & CEO of Skinvisible. "Our innovative topical formulations can deliver significant amounts of medication systemically, potentially avoiding the side effects associated with oral pills and injections while increasing patient compliance. Unlike pills that must pass through the digestive system and liver, potentially leading to uncomfortable side effects, our transdermal approach avoids first-pass metabolism. Additionally, our cream formulations offer a painless alternative to injections or serve as an effective maintenance therapy after patients reach their target weight. We are offering patients a more comfortable and convenient option for long-term management of their condition."
The U.S. Centers for Disease Control and Prevention (CDC) latest report states that four in every ten people are obese and that severe obesity is rising. According to a recent Morgan Stanley report, the market for obesity drugs globally could increase more than 15-fold by 2030, and is anticipated to reach
Skinvisible is actively seeking strategic partnerships with pharmaceutical and biotech companies to bring the first transdermal obesity therapies to market and explore broader applications of its delivery platform.
For more information on Skinvisible Pharmaceuticals, partnerships and investment opportunities, please visit www.skinvisible.com or contact info@skinvisible.com.
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals, a wholly-owned subsidiary of Skinvisible, Inc., is a pioneering research and development company specializing in licensing proprietary topical and transdermal formulations utilizing its patented polymer skin delivery system; Invisicare. This innovative technology provides life-cycle management and distinctive enhancements for both topical and transdermal delivery products. Invisicare formulated as a lotion or cream, effectively adheres active ingredients to the skin facilitating a controlled release of the active to and/or through the skin and into the blood stream over time. Skinvisible has recently developed formulations for the potential treatment of obesity, along with over forty dermatology related conditions including rare skin disorders. For further details, please visit www.skinvisible.com.
Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby including with respect to the possible development of any such products, the acceptance of any such products in the market place, the size of any such markets, the ability of any product candidates to be approved by the U.S. Food and Drug Administration among others. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward-looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the period ending June 30, 2024).
###
Contacts:
Strategic Partnerships: Doreen McMorran - doreen@invisicare.com
Corporate Inquiries: info@skinvisible.com
SOURCE: Skinvisible, Inc.
View the original press release on accesswire.com
FAQ
What is the transdermal penetration rate of Skinvisible's GLP-1 active formulation using Invisicare technology?
How does Skinvisible's Invisicare technology deliver medications for obesity treatment?
What are the potential advantages of Skinvisible's (SKVI) transdermal obesity formulations?
What is the projected market size for obesity drugs by 2030 according to the Skinvisible (SKVI) press release?
